These findings support the pathologic and molecular heterogeneity of medulloblastoma [57], [58] and suggest that in addition to a role in the diagnosis of pineal and retinal tumors, CRX immunohistochemistry may provide critical information in determining subtype classification and poor prognosis in cases of medulloblastoma [59]. The gene discussed is CRX; the disease is medulloblastoma.